

**Clinical Policy: Moxetumomab pasudotox-tdfk (Lumoxiti)**

Reference Number: CP.PHAR.398

Effective Date: 10.16.18

Last Review Date: 11.20

Line of Business: Commercial, HIM, Medicaid

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

**Description**

Moxetumomab pasudotox-tdfk (Lumoxiti<sup>™</sup>) is a CD22-directed cytotoxin.

**FDA Approved Indication(s)**

Lumoxiti is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).

Limitation(s) of use: Not recommended in patients with severe renal impairment ( $\text{CrCl} \leq 29$  mL/min).

**Policy/Criteria**

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of health plans affiliated with Centene Corporation<sup>®</sup> that Lumoxiti is **medically necessary** when the following criteria are met:

**I. Initial Approval Criteria**

**A. Hairy Cell Leukemia** (must meet all):

1. Diagnosis of HCL;
2. Prescribed by or in consultation with an oncologist or hematologist;
3. Age  $\geq 18$  years;
4. Disease is relapsed or refractory;
5. Received at least two prior systemic therapies (*see Appendix B for examples*), one of which must be a purine nucleoside analog (e.g., cladribine, Nipent<sup>®</sup>), unless all are contraindicated or clinically significant adverse effects are experienced;\*  
*\*Prior authorization may be required.*
6. Request meets one of the following (a or b):\*
  - a. Dose does not exceed 0.04 mg/kg/dose (actual body weight) for three days of each 28-day cycle;
  - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).*\*Prescribed regimen must be FDA-approved or recommended by NCCN.*

**Approval duration:**

**Medicaid/HIM** – 6 months

**Commercial** – 6 months or to the member's renewal date, whichever is longer

**B. Other diagnoses/indications**

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

**II. Continued Therapy**

**A. Hairy Cell Leukemia** (must meet all):

1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Lumoxiti for a covered indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. If request is for a dose increase, request meets one of the following (a or b):\*
  - a. New dose does not exceed 0.04 mg/kg/dose (actual body weight) for three days of each 28-day cycle;
  - b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

\*Prescribed regimen must be FDA-approved or recommended by NCCN.

**Approval duration:**

**Medicaid/HIM** – 12 months

**Commercial** – 6 months or to the member’s renewal date, whichever is longer

**B. Other diagnoses/indications** (must meet 1 or 2):

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.

**Approval duration: Duration of request or 6 months (whichever is less);** or

2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid or evidence of coverage documents.

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

CR: complete response

FDA: Food and Drug Administration

HCL: hairy cell leukemia

NCCN: National Comprehensive Cancer  
Cancer

PNA: purine nucleoside analog

*Appendix B: Therapeutic Alternatives*

*This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.*

<b>Drug Name</b>	<b>Dosing Regimen</b>	<b>Dose Limit/ Maximum Dose</b>
cladribine ( <i>purine analog</i> )	Adult dose: 0.09 mg/kg IV QD for 7 days (off-label SC dosing has been evaluated).	0.09 mg/kg/day
Nipent <sup>®</sup> (pentostatin) ( <i>purine analog</i> )	Adult dose: 4 mg/m <sup>2</sup> IV once every other week up to 6 months if failure to respond.	4 mg/m <sup>2</sup> /dose once every other week
Intron A <sup>®</sup> (interferon alfa-2b)	Adult dose: 2 million units/m <sup>2</sup> IM or SC 3 times a week for up to 6 months if failure to respond.	2 million units/m <sup>2</sup> /dose
Rituxan <sup>®</sup> (rituximab)	Off-label adult dose: 375 mg/m <sup>2</sup> IV weekly up to 10 weeks has been reported. (Micromedex)	Varies
Imbruvica <sup>®</sup> (ibrutinib)	Off-label adult dose: 420 mg PO QD in 28-day cycles until unacceptable toxicity or progressive disease. (Jones 2016)	Varies
Zelboraf <sup>®</sup> (vemurafenib)	Off-label adult dose: 960 mg PO BID for up to 24 weeks. (Clinical Pharmacology)	Varies

*Therapeutic alternatives are listed as Brand name<sup>®</sup> (generic) when the drug is available by brand name only and generic (Brand name<sup>®</sup>) when the drug is available by both brand and generic.*

*Appendix C: Contraindications/Boxed Warnings*

- Contraindication(s): none reported
- Boxed warning(s): capillary leak syndrome (CLS), hemolytic uremic syndrome (HUS)

*Appendix D: General Information*

The National Comprehensive Cancer Network (NCCN) HCL treatment recommendations:

- First-line therapy: purine analogs (cladribine, pentostatin).
- Second-line therapy for relapse/refractory or progressive disease:
  - Disease relapse  $\geq$  2 years after achieving CR to initial therapy:
    - Retreatment with the same purine analog  $\pm$  rituximab
    - An alternate purine analog  $\pm$  rituximab
    - Rituximab monotherapy if unable to receive a purine analog
  - Disease relapse  $<$  2 years after achieving CR to initial therapy:
    - An alternate purine analog  $\pm$  rituximab
    - Interferon alpha
    - Rituximab monotherapy if unable to receive purine analog
    - Vemurafenib
- Third-line therapy and beyond for progressive disease:
  - Vemurafenib  $\pm$  rituximab
  - Ibrutinib
  - Lumoxiti

**V. Dosage and Administration**

Indication	Dosing Regimen	Maximum Dose
HCL	0.04 mg/kg IV on Days 1, 3, and 5 of each 28-day cycle. Continue treatment for maximum of 6 cycles, disease progression, or unacceptable toxicity.	0.04 mg/kg/dose (actual body weight)

## VI. Product Availability

Single-dose vial: 1 mg

## VII. References

1. Lumoxiti Prescribing Information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; April 2020. Available at: <https://www.lumoxiti.com/>. Accessed August 17, 2020.
2. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at [nccn.org](http://nccn.org). Accessed August 17, 2020.
3. National Comprehensive Cancer Network Guidelines. Hairy Cell Leukemia Version 1.2020. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/hairy\\_cell.pdf](https://www.nccn.org/professionals/physician_gls/pdf/hairy_cell.pdf). Accessed August 17, 2020.
4. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2020. Available at: <http://www.clinicalpharmacology-ip.com/>. Accessed August 17, 2020.
5. Micromedex Healthcare Series [Internet database]. Greenwood Village, Colo: Thomson Healthcare. Updated periodically. Accessed August 17, 2020.
6. Jones J, Andritsos L, Kreitman RJ, et al. (2016). Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study. *Blood*, 128(22), 1215.
7. Tiacci E, Park JH, De Carolis L, et al. Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. *N Engl J Med*. 2015 Oct 29;373(18):1733-47. doi: 10.1056/NEJMoa1506583. Epub 2015 Sep 9.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created	10.16.18	11.18
4Q 2019 annual review: cycle details added to FDA dosing; FDA/NCCN dosing limitations added; references reviewed and updated.	8.20.19	11.19
4Q 2020 annual review: modified HIM-Medical Benefit to HIM line of business; no significant changes; references reviewed and updated.	08.17.20	11.20

## **Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in

developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note:**

**For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2018 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international

copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene<sup>®</sup> and Centene Corporation<sup>®</sup> are registered trademarks exclusively owned by Centene Corporation.